Compare MCD & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCD | MRK |
|---|---|---|
| Founded | 1940 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.3B | 268.7B |
| IPO Year | 1995 | 1994 |
| Metric | MCD | MRK |
|---|---|---|
| Price | $324.86 | $116.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 14 |
| Target Price | ★ $342.21 | $123.21 |
| AVG Volume (30 Days) | 3.1M | ★ 8.5M |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | 2.27% | ★ 2.90% |
| EPS Growth | 4.92 | ★ 8.01 |
| EPS | ★ 11.95 | 7.28 |
| Revenue | $26,885,000,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $8.05 | $3.74 |
| Revenue Next Year | $5.72 | $5.47 |
| P/E Ratio | $27.49 | ★ $16.10 |
| Revenue Growth | ★ 3.72 | 1.31 |
| 52 Week Low | $283.47 | $75.40 |
| 52 Week High | $341.75 | $125.14 |
| Indicator | MCD | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 46.72 | 46.17 |
| Support Level | $320.15 | $105.23 |
| Resistance Level | $335.67 | $125.14 |
| Average True Range (ATR) | 4.74 | 2.81 |
| MACD | -1.57 | -1.09 |
| Stochastic Oscillator | 17.43 | 20.89 |
McDonald's is the world's largest restaurant brand, with nearly $131 billion in systemwide sales across more than 44,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 61%), with the remainder stemming from company-operated restaurants across three segments: the United States (41% of systemwide sales), international operated markets (34%), and international developmental/licensed markets (25%).
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).